1. Home
  2. ABEO vs SNFCA Comparison

ABEO vs SNFCA Comparison

Compare ABEO & SNFCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • SNFCA
  • Stock Information
  • Founded
  • ABEO N/A
  • SNFCA 1965
  • Country
  • ABEO United States
  • SNFCA United States
  • Employees
  • ABEO N/A
  • SNFCA N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • SNFCA Finance: Consumer Services
  • Sector
  • ABEO Health Care
  • SNFCA Finance
  • Exchange
  • ABEO Nasdaq
  • SNFCA Nasdaq
  • Market Cap
  • ABEO 243.9M
  • SNFCA 285.8M
  • IPO Year
  • ABEO 1980
  • SNFCA N/A
  • Fundamental
  • Price
  • ABEO $5.19
  • SNFCA $12.64
  • Analyst Decision
  • ABEO Strong Buy
  • SNFCA
  • Analyst Count
  • ABEO 3
  • SNFCA 0
  • Target Price
  • ABEO $18.00
  • SNFCA N/A
  • AVG Volume (30 Days)
  • ABEO 251.8K
  • SNFCA 34.1K
  • Earning Date
  • ABEO 11-14-2024
  • SNFCA 11-14-2024
  • Dividend Yield
  • ABEO N/A
  • SNFCA N/A
  • EPS Growth
  • ABEO N/A
  • SNFCA N/A
  • EPS
  • ABEO N/A
  • SNFCA 1.23
  • Revenue
  • ABEO N/A
  • SNFCA $330,162,091.00
  • Revenue This Year
  • ABEO N/A
  • SNFCA N/A
  • Revenue Next Year
  • ABEO $15,721.96
  • SNFCA N/A
  • P/E Ratio
  • ABEO N/A
  • SNFCA $10.01
  • Revenue Growth
  • ABEO 147.52
  • SNFCA N/A
  • 52 Week Low
  • ABEO $3.05
  • SNFCA $6.19
  • 52 Week High
  • ABEO $9.01
  • SNFCA $13.59
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 34.35
  • SNFCA 61.86
  • Support Level
  • ABEO $5.05
  • SNFCA $11.26
  • Resistance Level
  • ABEO $5.66
  • SNFCA $12.32
  • Average True Range (ATR)
  • ABEO 0.27
  • SNFCA 0.33
  • MACD
  • ABEO -0.06
  • SNFCA 0.05
  • Stochastic Oscillator
  • ABEO 13.21
  • SNFCA 99.93

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

Share on Social Networks: